Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 11 August 2026(4 announcements)

Zydus Lifesciences announced that an audio recording of its investor call discussing unaudited financial results for the quarter ended June 30, 2026, is now available on its website via a provided link.

Zydus Lifesciences reported total revenues of Rs. 80,170 million for Q1 FY27, reflecting a 22% year-on-year growth driven by strong performance across its pharmaceutical, international, and consumer wellness segments. EBITDA margin declined to 24.1% from 31.8% YoY due to rising costs and foreign exchange losses, while net profit fell 35.9% to Rs. 9,398 million. The company highlighted robust branded business growth in India, new product launches in North America, and expansion in biosimilars and medtech. Regulatory updates included a VAI classification for its injectable facility and priority review for a key liver disease drug. Capex stood at Rs. 5,852 million, and net debt reached Rs. 59,041 million. The presentation emphasized sustainable growth, ESG commitments, and pipeline advancements.

Zydus Lifesciences reported Q1 FY27 revenue of ₹80,170 crores, up 22% YoY, but net profit fell 36% to ₹9,398 crores due to margin pressure. EBITDA declined 8% YoY to ₹19,294 crores, with margin compressing to 24.1% from 31.8% a year ago. The company highlighted strong branded growth in the US (11% share) and launched its first biosimilar, NUFYMCO™. Capex stood at ₹5,852 crores, while net debt to equity improved to 0.22x. Despite top-line growth, profitability and margin expansion remain key concerns for investors.

Zydus Lifesciences shareholders approved all 9 AGM resolutions with near-unanimous support, including adoption of audited financial statements, declaration of a final dividend of ₹1 per share, and re-appointments of key directors like Pankaj R. Patel and Mukesh M. Patel. The meeting, held on August 11, 2026, via video conferencing, saw 917,774,025 votes in favor for financial statements and 918,121,541 for dividend approval, reflecting strong endorsement of management and governance decisions.